Cyclam-Modified PEI for Combined VEGF siRNA Silencing and CXCR4 Inhibition to Treat Metastatic Breast Cancer

Yiwen Zhou, Fei Yu, Feiran Zhang, Gang Chen, Kaikai Wang, Minjie Sun, Jing Li, David Oupicky

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Chemokine receptor CXCR4 plays an important role in cancer cell invasion and metastasis. Recent findings suggest that anti-VEGF therapies upregulate CXCR4 expression, which contributes to resistance to antiangiogenic therapies. Here, we report the development of novel derivatives of polyethylenimine (PEI) that effectively inhibit CXCR4 while delivering anti-VEGF siRNA. PEI was alkylated with different amounts of a CXCR4-binding cyclam derivative to prepare PEI-C. Modification with the cyclam derivatives resulted in a considerable decrease in cytotoxicity when compared with unmodified PEI. All the PEI-C showed significant CXCR4 antagonism and the ability to inhibit cancer cell invasion. Polyplexes of PEI-C prepared with siVEGF showed effective silencing of the VEGF expression in vitro. In vivo testing in a syngeneic breast cancer model showed promising antitumor and antimetastatic activity of the PEI-C/siVEGF polyplexes. Our data demonstrate the feasibility of using PEI-C as a carrier for simultaneous VEGF silencing and CXCR4 inhibition for enhanced antiangiogenic cancer therapies.

Original languageEnglish (US)
Pages (from-to)392-401
Number of pages10
JournalBiomacromolecules
Volume19
Issue number2
DOIs
StatePublished - Feb 12 2018

Fingerprint

Polyethyleneimine
Vascular Endothelial Growth Factor A
Small Interfering RNA
Derivatives
Cells
Cytotoxicity
Testing
cyclam
Chemokine Receptors

ASJC Scopus subject areas

  • Bioengineering
  • Biomaterials
  • Polymers and Plastics
  • Materials Chemistry

Cite this

Cyclam-Modified PEI for Combined VEGF siRNA Silencing and CXCR4 Inhibition to Treat Metastatic Breast Cancer. / Zhou, Yiwen; Yu, Fei; Zhang, Feiran; Chen, Gang; Wang, Kaikai; Sun, Minjie; Li, Jing; Oupicky, David.

In: Biomacromolecules, Vol. 19, No. 2, 12.02.2018, p. 392-401.

Research output: Contribution to journalArticle

Zhou, Yiwen ; Yu, Fei ; Zhang, Feiran ; Chen, Gang ; Wang, Kaikai ; Sun, Minjie ; Li, Jing ; Oupicky, David. / Cyclam-Modified PEI for Combined VEGF siRNA Silencing and CXCR4 Inhibition to Treat Metastatic Breast Cancer. In: Biomacromolecules. 2018 ; Vol. 19, No. 2. pp. 392-401.
@article{dcfd847d975340bba465f5b21230167c,
title = "Cyclam-Modified PEI for Combined VEGF siRNA Silencing and CXCR4 Inhibition to Treat Metastatic Breast Cancer",
abstract = "Chemokine receptor CXCR4 plays an important role in cancer cell invasion and metastasis. Recent findings suggest that anti-VEGF therapies upregulate CXCR4 expression, which contributes to resistance to antiangiogenic therapies. Here, we report the development of novel derivatives of polyethylenimine (PEI) that effectively inhibit CXCR4 while delivering anti-VEGF siRNA. PEI was alkylated with different amounts of a CXCR4-binding cyclam derivative to prepare PEI-C. Modification with the cyclam derivatives resulted in a considerable decrease in cytotoxicity when compared with unmodified PEI. All the PEI-C showed significant CXCR4 antagonism and the ability to inhibit cancer cell invasion. Polyplexes of PEI-C prepared with siVEGF showed effective silencing of the VEGF expression in vitro. In vivo testing in a syngeneic breast cancer model showed promising antitumor and antimetastatic activity of the PEI-C/siVEGF polyplexes. Our data demonstrate the feasibility of using PEI-C as a carrier for simultaneous VEGF silencing and CXCR4 inhibition for enhanced antiangiogenic cancer therapies.",
author = "Yiwen Zhou and Fei Yu and Feiran Zhang and Gang Chen and Kaikai Wang and Minjie Sun and Jing Li and David Oupicky",
year = "2018",
month = "2",
day = "12",
doi = "10.1021/acs.biomac.7b01487",
language = "English (US)",
volume = "19",
pages = "392--401",
journal = "Biomacromolecules",
issn = "1525-7797",
publisher = "American Chemical Society",
number = "2",

}

TY - JOUR

T1 - Cyclam-Modified PEI for Combined VEGF siRNA Silencing and CXCR4 Inhibition to Treat Metastatic Breast Cancer

AU - Zhou, Yiwen

AU - Yu, Fei

AU - Zhang, Feiran

AU - Chen, Gang

AU - Wang, Kaikai

AU - Sun, Minjie

AU - Li, Jing

AU - Oupicky, David

PY - 2018/2/12

Y1 - 2018/2/12

N2 - Chemokine receptor CXCR4 plays an important role in cancer cell invasion and metastasis. Recent findings suggest that anti-VEGF therapies upregulate CXCR4 expression, which contributes to resistance to antiangiogenic therapies. Here, we report the development of novel derivatives of polyethylenimine (PEI) that effectively inhibit CXCR4 while delivering anti-VEGF siRNA. PEI was alkylated with different amounts of a CXCR4-binding cyclam derivative to prepare PEI-C. Modification with the cyclam derivatives resulted in a considerable decrease in cytotoxicity when compared with unmodified PEI. All the PEI-C showed significant CXCR4 antagonism and the ability to inhibit cancer cell invasion. Polyplexes of PEI-C prepared with siVEGF showed effective silencing of the VEGF expression in vitro. In vivo testing in a syngeneic breast cancer model showed promising antitumor and antimetastatic activity of the PEI-C/siVEGF polyplexes. Our data demonstrate the feasibility of using PEI-C as a carrier for simultaneous VEGF silencing and CXCR4 inhibition for enhanced antiangiogenic cancer therapies.

AB - Chemokine receptor CXCR4 plays an important role in cancer cell invasion and metastasis. Recent findings suggest that anti-VEGF therapies upregulate CXCR4 expression, which contributes to resistance to antiangiogenic therapies. Here, we report the development of novel derivatives of polyethylenimine (PEI) that effectively inhibit CXCR4 while delivering anti-VEGF siRNA. PEI was alkylated with different amounts of a CXCR4-binding cyclam derivative to prepare PEI-C. Modification with the cyclam derivatives resulted in a considerable decrease in cytotoxicity when compared with unmodified PEI. All the PEI-C showed significant CXCR4 antagonism and the ability to inhibit cancer cell invasion. Polyplexes of PEI-C prepared with siVEGF showed effective silencing of the VEGF expression in vitro. In vivo testing in a syngeneic breast cancer model showed promising antitumor and antimetastatic activity of the PEI-C/siVEGF polyplexes. Our data demonstrate the feasibility of using PEI-C as a carrier for simultaneous VEGF silencing and CXCR4 inhibition for enhanced antiangiogenic cancer therapies.

UR - http://www.scopus.com/inward/record.url?scp=85041919509&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041919509&partnerID=8YFLogxK

U2 - 10.1021/acs.biomac.7b01487

DO - 10.1021/acs.biomac.7b01487

M3 - Article

C2 - 29350899

AN - SCOPUS:85041919509

VL - 19

SP - 392

EP - 401

JO - Biomacromolecules

JF - Biomacromolecules

SN - 1525-7797

IS - 2

ER -